{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:29:35Z","timestamp":1758814175246,"version":"3.44.0"},"reference-count":28,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,7,13]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Coexistence of idiopathic Parkinson\u2019s disease (iPD) and schizophrenia can pose great diagnostic and therapeutic challenges because of their pathophysiology. Our case highlights such challenges in management. We present a case of 73-year-old man who had parkinsonism for last several years and was also diagnosed with schizophrenia. Due to lack of collateral information about the onset of symptoms and clinical course, it was difficult to distinguish iPD from neuroleptic-induced parkinsonism. Even though, certain clinical findings may help to differentiate between the two conditions, single positron emission computerized tomography\/DatScan was used to confirm the diagnosis of iPD. Treatment of coexisting iPD and schizophrenia can be challenging, and a delicate pharmacologic balance must be maintained to ensure adequate symptomatic control. Current evidence suggests that clozapine is a better choice for managing psychosis in these patients due to its unique receptor profile and better safety data.<\/jats:p>","DOI":"10.1136\/bcr-2021-244028","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:58:50Z","timestamp":1627559930000},"page":"e244028","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Novel case of Parkinson\u2019s disease and schizophrenia: challenges in the management"],"prefix":"10.1136","volume":"14","author":[{"given":"Amna","family":"Ramzan","sequence":"first","affiliation":[{"name":"Department of Neurology, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariha","family":"Jamal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2025082710074379000_14.7.e244028.1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131045"},{"key":"2025082710074379000_14.7.e244028.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.12.060"},{"key":"2025082710074379000_14.7.e244028.3","unstructured":"Hany M , Rehman B , Azhar Y . Schizophrenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021."},{"key":"2025082710074379000_14.7.e244028.4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1440-1819.2006.01572.x","article-title":"Paranoid schizophrenia and idiopathic Parkinson's disease do coexist: a challenge for clinicians","volume":"60","author":"Winter","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"2025082710074379000_14.7.e244028.5","doi-asserted-by":"crossref","unstructured":"Gadit A , Gadit A , Gait A . Schizophrenia and Parkinson\u2019s disease: Challenges in management. BMJ Case Rep 2011.doi:10.1136\/bcr.11.2011.5108","DOI":"10.1136\/bcr.11.2011.5108"},{"key":"2025082710074379000_14.7.e244028.6","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200103000-00011"},{"key":"2025082710074379000_14.7.e244028.7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00002826-198710000-00011","article-title":"Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa","volume":"10","author":"Friedman","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"2025082710074379000_14.7.e244028.8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/070674379303800201","article-title":"Chronic schizophrenia and idiopathic Parkinson's disease","volume":"38","author":"Lam","year":"1993","journal-title":"Can J Psychiatry"},{"key":"2025082710074379000_14.7.e244028.9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0924-9338(03)00068-3","article-title":"Comorbidity of parkinsonism and schizophrenia in a patient treated with clozapine","volume":"18","author":"Urban","year":"2003","journal-title":"Eur Psychiatry"},{"key":"2025082710074379000_14.7.e244028.10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20.3.373"},{"key":"2025082710074379000_14.7.e244028.11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1440-1819.2009.02050.x","article-title":"Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia","volume":"64","author":"Fujino","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"2025082710074379000_14.7.e244028.12","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2012.8.1.15"},{"key":"2025082710074379000_14.7.e244028.13","doi-asserted-by":"publisher","DOI":"10.1007\/s007020100006"},{"key":"2025082710074379000_14.7.e244028.14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20748"},{"key":"2025082710074379000_14.7.e244028.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0208-x"},{"key":"2025082710074379000_14.7.e244028.16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21382"},{"key":"2025082710074379000_14.7.e244028.17","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/645429"},{"key":"2025082710074379000_14.7.e244028.18","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.139"},{"key":"2025082710074379000_14.7.e244028.19","doi-asserted-by":"crossref","unstructured":"Cummings J , Isaacson S , Mills R . Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial 2014;384.","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"2025082710074379000_14.7.e244028.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442552"},{"key":"2025082710074379000_14.7.e244028.21","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q"},{"key":"2025082710074379000_14.7.e244028.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000236769.31279.19"},{"key":"2025082710074379000_14.7.e244028.23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.48.3.658","article-title":"Low-Dose clozapine improves dyskinesias in Parkinson's disease","volume":"48","author":"Durif","year":"1997","journal-title":"Neurology"},{"key":"2025082710074379000_14.7.e244028.24","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016040-00003"},{"key":"2025082710074379000_14.7.e244028.25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/NDT.S83989","article-title":"Rare and very rare adverse effects of clozapine","volume":"11","author":"De Fazio","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025082710074379000_14.7.e244028.26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00702-014-1212-4","article-title":"Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms","volume":"121","author":"Nishioka","year":"2014","journal-title":"J Neural Transm"},{"key":"2025082710074379000_14.7.e244028.27","doi-asserted-by":"publisher","DOI":"10.1097\/YCT.0b013e3181c18a3d"},{"key":"2025082710074379000_14.7.e244028.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.05.003"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-244028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:07:50Z","timestamp":1756314470000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-244028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,29]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bcr-2021-244028"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-244028","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}